Wegovy regulates appetite by mimicking the GLP-1 hormone, which increases insulin secretion, slows gastric emptying, and reduces appetite, helping individuals to feel fuller longer and eat less
May have other health benefits
Workflows where convenience matters and the 5:1:1 GHK-Cu-dominant ratio fits the goal
Eli Lilly, the maker of Zepbound and Mounjaro, is also taking a firm stance
(Given the potential long-term consequences of NMOSD relapses, the company could not ethically include a direct placebo arm in its Phase III trial.) Ultomiris was well-tolerated overall, and most treatment-emergent events were mild or moderate in severity, according to AstraZeneca
And weight loss on these drugs tends to slow the longer people stay on them